Phase 1a/1b Trial of LTI-01 (Single Chain Urokinase, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions or Empyema

Trial Profile

Phase 1a/1b Trial of LTI-01 (Single Chain Urokinase, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions or Empyema

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs LTI 01 (Primary)
  • Indications Acute lung injury; Idiopathic pulmonary fibrosis; Pleural effusion
  • Focus Adverse reactions
  • Sponsors Lung Therapeutics
  • Most Recent Events

    • 14 Mar 2017 According to a Lung Therapeutics media release, first patient has been enrolled and dosed in the study.
    • 14 Mar 2017 Status changed from not yet recruiting to recruiting, as reported in a Lung Therapeutics media release.
    • 15 Oct 2016 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top